TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06940180: Toripalimab With Chemotherapy for Sinus Cancer

Sponsor: Dana-Farber Cancer Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$739,200

Rescue Site Savings

+$508,200

Unlock Full NCT06940180 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06940180 Rescue Dossier →